



HUTCHISON CHINA MEDITECH

## Blocklisting Six Monthly Return

**London: Thursday, December 31, 2020:** Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:

1. Name of applicant: Hutchison China MediTech Limited
2. Name of scheme:
  - (a) Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2005 (“2005 HCML Share Option Scheme”)
  - (b) Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2015 (“2015 HCML Share Option Scheme”)
  - (c) Warrant instrument granted by Hutchison China MediTech Limited on June 25, 2020 (“Warrant”)
3. Period of return: From June 29, 2020 to December 28, 2020
4. Balance under scheme from previous return:
  - (a) 2005 HCML Share Option Scheme: 1,738,910 ordinary shares of US\$0.1 each
  - (b) 2015 HCML Share Option Scheme: 23,130,970 ordinary shares of US\$0.1 each
5. The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:
  - (a) 2005 HCML Share Option Scheme: Nil
  - (b) 2015 HCML Share Option Scheme: 30,221,458 ordinary shares of US\$0.1 each
  - (c) Warrant: 16,666,670 ordinary shares of US\$0.1 each
6. Number of securities issued/allotted under scheme during period:
  - (a) 2005 HCML Share Option Scheme: 400,000 ordinary shares of US\$0.1 each
  - (b) 2015 HCML Share Option Scheme: 80,780 ordinary shares of US\$0.1 each
  - (c) Warrant: nil
7. Balance under scheme not yet issued/allotted at end of the period:
  - (a) 2005 HCML Share Option Scheme: 1,338,910 ordinary shares of US\$0.1 each
  - (b) 2015 HCML Share Option Scheme: 53,271,648 ordinary shares of US\$0.1 each
  - (c) Warrant: 16,666,670 ordinary shares of US\$0.1 each
8. Number and class of securities originally listed and the date of admission:
  - (a) 25,198,880 ordinary shares of US\$0.1 each admitted on June 17, 2019 (to replace the Company’s previous block admission schemes following the Company’s share subdivision which took effect on May 30, 2019)
  - (b) 16,666,670 ordinary shares of US\$0.1 each admitted on July 6, 2020

9. Total number of securities in issue at the end of the period: 727,722,215 ordinary shares of US\$0.1 each

Name of contact: Christian Hogg

Address of contact: Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong

Telephone number of contact: +852 2121 8200

### **About Chi-Med**

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: [www.chi-med.com](http://www.chi-med.com).

### **CONTACTS**

#### **Investor Enquiries**

Mark Lee, Senior Vice President +852 2121 8200  
Annie Cheng, Vice President +1 (973) 567 3786

#### **Media Enquiries**

**Americas** – Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)  
[bmiles@troutgroup.com](mailto:bmiles@troutgroup.com)  
**Europe** – Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)  
[Chi-Med@fticonsulting.com](mailto:Chi-Med@fticonsulting.com)  
**Asia** – Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile), [jlo@brunswickgroup.com](mailto:jlo@brunswickgroup.com) /  
+852 9783 6894 (Mobile), [yzhou@brunswickgroup.com](mailto:yzhou@brunswickgroup.com)

#### **Nominated Advisor**

Freddy Crossley / Atholl Tweedie, Panmure Gordon +44 (20) 7886 2500  
(UK) Limited